3
GHA-accredited longevity providers in the founding pilot
25-90
consecutive eligible adults enrolled per provider
90 Days
to the planned follow-up contact
5
core quality and safety measures
The registry is designed to show whether longevity care continues after a patient leaves the clinic, including when care takes place away from home. Many longevity patients receive care through , also called medical tourism, or in residential and hospitality wellness settings.
The founding pilot records wheter each patient traveled for care. Later modules for medical travel and residential settings will add detail as accredited sites in those programs join.
The registry's founding pilot is planned with three GHA-accredited longevity providers in one region, each enrolling 25 to 50 consecutive eligible adults starting a new outpatient longevity care program.
Consecutive enrollment means every eligible patient is invited, so the registry reflects routine care rather than selected cases. The pilot tests whether the information can be collected reliably and with a practical workload.
Yes. GHA Living Evidence is a quality and safety registry: it collects uniform information about a defined group of patients to measure quality of care and monitor safety. It is not currently a research study. Any future research use will require its own protocol and appropriate ethics review.
A clinical trial assigns patients to treatments under a research protocol to test whether a treatment works. A registry such as GHA Living Evidence observes routine care as it happens, without directing which treatments patients receive, to measure quality and monitor safety.
The founding pilot is open to GHA-accredited longevity providers, or providers completing accreditation before enrollment, that have the staff and systems to follow patients for about 90 days. Eligibility will be confirmed before enrollment.
Patient enrollment has not yet started. The founding pilot will begin enrolling after final measures and timing are confirmed through scientific review and participating providers are confirmed. The registry status at the top of this page shows the current stage.
No. Taking part in the registry does not create a separate award, endorse any treatment or affect accreditation decisions. Accreditation decisions remain within GHA's accreditation process.
No. The GHA Living Evidence Registry describes care processes, patient-reported progress and safety follow-up. These observations help clinics improve and can identify questions for further study, but they cannot show that a treatment caused a health improvement or extended life.
Every registry record notes whether the patient traveled for care, and handovers to a clinician in another region or country are reported separately. This shows whether care continues after a medical travel patient returns home. A dedicated medical travel module is planned for a later phase.
Patients of participating clinics may be asked to choose a care goal and answer brief follow-up questions about progress and problems since care began. Clinics explain participation choices before enrollment. Choices do not affect access to care.
Participating clinics receive private results, and the registry does not rank clinics. Any aggregate report will be reviewed for accuracy and privacy and will state the number of sites, number of patients, missing information and limitations.
No. GHA does not sell patient-level registry data. Access to aggregate information will follow a data access and use policy, published after the scientific committee approves it.
No. The registry supports periodic quality review, not medical advice or urgent clinical monitoring. Patients continue to receive care from their treating team and should contact their clinician or emergency services when needed.
Complete the founding pilot inquiry form with your organization, location, role, care setting and accreditation status. GHA will contact you about scope, readiness requirements and next steps.
GHA invites accredited longevity providers to help establish a consistent, independently governed registry for longevity medicine. Start with a manageable set of measures and contribute to evidence that keeps developing.